MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
MIRA Pharmaceuticals (NASDAQ:MIRA) has signed a binding letter of intent to acquire SKNY Pharmaceuticals, securing a $5 million capital infusion. The acquisition includes SKNY-1, a preclinical-stage oral drug candidate targeting weight loss and smoking cessation.
The transaction will be executed through a stock exchange, with SKNY shareholders receiving MIRA common stock at a valuation determined by an independent third-party firm. The deal positions MIRA in two significant markets: the weight loss drug market, projected to exceed $150 billion by early 2030s, and the smoking cessation market, expected to reach $51 billion by 2030.
SKNY-1 is being developed to interact with cannabinoid receptors CB1 and CB2 pathways for appetite, metabolism, and energy balance regulation. The drug aims to address limitations of current treatments, including severe side effects and the need for lifelong injections in existing weight loss medications.
The transaction is subject to a 90-day due diligence period, regulatory approvals, and board approvals.
MIRA Pharmaceuticals (NASDAQ:MIRA) ha firmato una lettera di intenti vincolante per acquisire SKNY Pharmaceuticals, assicurandosi un'infusione di capitale di 5 milioni di dollari. L'acquisizione include SKNY-1, un candidato farmaco orale in fase preclinica mirato alla perdita di peso e alla cessazione del fumo.
La transazione sarà eseguita tramite uno scambio di azioni, con gli azionisti di SKNY che riceveranno azioni ordinarie di MIRA a una valutazione stabilita da una società indipendente di terze parti. L'accordo posiziona MIRA in due mercati significativi: il mercato dei farmaci per la perdita di peso, previsto superare i 150 miliardi di dollari all'inizio degli anni 2030, e il mercato per la cessazione del fumo, che si prevede raggiunga i 51 miliardi di dollari entro il 2030.
SKNY-1 è in fase di sviluppo per interagire con i recettori cannabinoidi CB1 e CB2 per la regolazione dell'appetito, del metabolismo e dell'equilibrio energetico. Il farmaco mira a risolvere le limitazioni dei trattamenti attuali, inclusi gravi effetti collaterali e la necessità di iniezioni a vita nei farmaci per la perdita di peso esistenti.
La transazione è soggetta a un periodo di due diligence di 90 giorni, approvazioni regolatorie e approvazioni del consiglio.
MIRA Pharmaceuticals (NASDAQ:MIRA) ha firmado una carta de intención vinculante para adquirir SKNY Pharmaceuticals, asegurando una inyección de capital de 5 millones de dólares. La adquisición incluye SKNY-1, un candidato a fármaco oral en etapa preclínica dirigido a la pérdida de peso y a la cesación del tabaquismo.
La transacción se llevará a cabo mediante un intercambio de acciones, con los accionistas de SKNY recibiendo acciones comunes de MIRA a una valoración determinada por una firma independiente de terceros. El acuerdo posiciona a MIRA en dos mercados significativos: el mercado de medicamentos para la pérdida de peso, que se proyecta que superará los 150 mil millones de dólares a principios de la década de 2030, y el mercado de cesación del tabaquismo, que se espera alcance los 51 mil millones de dólares para 2030.
SKNY-1 está siendo desarrollado para interactuar con los receptores cannabinoides CB1 y CB2 para la regulación del apetito, el metabolismo y el equilibrio energético. El fármaco busca abordar las limitaciones de los tratamientos actuales, incluidos los efectos secundarios severos y la necesidad de inyecciones de por vida en los medicamentos existentes para la pérdida de peso.
La transacción está sujeta a un período de diligencia debida de 90 días, aprobaciones regulatorias y aprobaciones de la junta.
MIRA Pharmaceuticals (NASDAQ:MIRA)는 SKNY Pharmaceuticals 인수를 위한 구속력 있는 의향서를 체결하고 500만 달러의 자본 투입을 확보했습니다. 이번 인수에는 체중 감소 및 금연을 목표로 하는 전임상 단계의 경구 약물 후보인 SKNY-1이 포함됩니다.
거래는 주식 교환을 통해 실행되며, SKNY 주주들은 독립적인 제3자 회사가 정한 평가에 따라 MIRA의 보통주를 받게 됩니다. 이 거래는 MIRA를 두 개의 중요한 시장에 위치시킵니다: 체중 감소 약물 시장은 2030년대 초까지 1,500억 달러를 초과할 것으로 예상되며, 금연 시장은 2030년까지 510억 달러에 이를 것으로 예상됩니다.
SKNY-1은 식욕, 신진대사 및 에너지 균형 조절을 위해 CB1 및 CB2 칸나비노이드 수용체와 상호작용하도록 개발되고 있습니다. 이 약물은 기존 체중 감소 약물의 심각한 부작용과 평생 주사 필요성 등 현재 치료의 한계를 해결하는 것을 목표로 하고 있습니다.
이 거래는 90일의 실사 기간, 규제 승인 및 이사회 승인에 따라 진행됩니다.
MIRA Pharmaceuticals (NASDAQ:MIRA) a signé une lettre d'intention contraignante pour acquérir SKNY Pharmaceuticals, garantissant une injection de capital de 5 millions de dollars. L'acquisition comprend SKNY-1, un candidat médicament oral en phase préclinique visant à la perte de poids et à l'arrêt du tabac.
La transaction sera réalisée par le biais d'un échange d'actions, les actionnaires de SKNY recevant des actions ordinaires de MIRA à une valorisation déterminée par une société indépendante tierce. Cet accord positionne MIRA sur deux marchés significatifs : le marché des médicaments pour la perte de poids, qui devrait dépasser 150 milliards de dollars au début des années 2030, et le marché de l'arrêt du tabac, qui devrait atteindre 51 milliards de dollars d'ici 2030.
SKNY-1 est en cours de développement pour interagir avec les récepteurs cannabinoïdes CB1 et CB2 pour la régulation de l'appétit, du métabolisme et de l'équilibre énergétique. Le médicament vise à résoudre les limitations des traitements actuels, y compris des effets secondaires graves et la nécessité d'injections à vie dans les médicaments existants pour la perte de poids.
La transaction est soumise à une période de due diligence de 90 jours, à des approbations réglementaires et à des approbations du conseil d'administration.
MIRA Pharmaceuticals (NASDAQ:MIRA) hat ein verbindliches Absichtsschreiben zur Übernahme von SKNY Pharmaceuticals unterzeichnet und sich damit eine Kapitalzufuhr von 5 Millionen Dollar gesichert. Die Übernahme umfasst SKNY-1, einen oralen Wirkstoffkandidaten in der präklinischen Phase, der auf Gewichtsverlust und Raucherentwöhnung abzielt.
Die Transaktion wird durch einen Aktienaustausch durchgeführt, wobei die SKNY-Aktionäre MIRA-Stammaktien zu einer Bewertung erhalten, die von einer unabhängigen Drittpartei festgelegt wird. Der Deal positioniert MIRA in zwei bedeutenden Märkten: dem Markt für Gewichtsverlustmedikamente, der voraussichtlich bis Anfang der 2030er Jahre 150 Milliarden Dollar übersteigen wird, und dem Markt für Raucherentwöhnung, der bis 2030 voraussichtlich 51 Milliarden Dollar erreichen wird.
SKNY-1 wird entwickelt, um mit den Cannabinoid-Rezeptoren CB1 und CB2 für die Regulierung von Appetit, Stoffwechsel und Energiebilanz zu interagieren. Das Medikament zielt darauf ab, die Einschränkungen der aktuellen Behandlungen, einschließlich schwerer Nebenwirkungen und der Notwendigkeit lebenslanger Injektionen bei bestehenden Gewichtsverlustmedikamenten, zu adressieren.
Die Transaktion unterliegt einer 90-tägigen Due-Diligence-Phase, regulatorischen Genehmigungen und Genehmigungen des Vorstands.
- $5 million capital infusion strengthens MIRA's financial position
- Entry into two high-growth markets: weight loss ($150B by 2030s) and smoking cessation ($51B by 2030)
- Potential competitive advantage with oral therapeutic vs. injectable competitors
- Acquisition includes full intellectual property rights for SKNY-1
- SKNY-1 still in preclinical stage, far from commercialization
- Potential shareholder dilution through stock-based acquisition
- 90-day due diligence period and regulatory approvals create execution risk
- No proven efficacy data presented for SKNY-1
Insights
MIRA's acquisition of SKNY Pharmaceuticals represents a strategic expansion with both immediate financial benefits and long-term growth potential. The
The deal structure warrants attention: MIRA will acquire SKNY through a stock exchange, with an independent third-party determining valuation. This approach will result in dilution for existing shareholders, though the extent remains undefined until valuation details emerge. Importantly, SKNY's commitment to contribute
From a market opportunity perspective, this acquisition positions MIRA in two high-growth pharmaceutical sectors. The weight loss market, projected to reach
While the capital infusion and market positioning are positive, investors should recognize that SKNY-1 remains in preclinical development - placing it years away from potential commercialization and revenue generation. The 90-day due diligence period and regulatory approval requirements also introduce execution risk before this binding LOI converts to a completed transaction.
SKNY-1 represents an intriguing scientific approach targeting the cannabinoid receptor system, specifically CB1 and CB2 pathways, for dual indications in weight management and smoking cessation. The strategic rationale is sound - both conditions share neurobiological mechanisms related to reward pathways and addiction, potentially allowing one compound to address two significant health challenges.
From a competitive standpoint, an oral therapeutic for weight loss would differentiate from market-leading GLP-1 receptor agonists that require injection and often cause significant gastrointestinal side effects. In smoking cessation, where current FDA-approved treatments show efficacy and poor adherence, a novel mechanism of action could potentially address unmet needs.
However, SKNY-1's preclinical status represents significant development risk. The compound must still navigate IND-enabling studies, Phase 1 safety trials, and efficacy studies before reaching pivotal trials. This developmental pathway typically spans 5-7 years with costs reaching hundreds of millions - far exceeding the
The pharmacological rationale appears promising, as cannabinoid receptor modulation has established scientific validity in metabolic regulation and addiction mechanisms. Dr. Angel's endorsement of the preclinical data adds credibility, though details on specific outcomes remain Investors should understand that preclinical promise frequently fails to translate to human efficacy, with industry-wide success rates for CNS-targeting compounds notably low compared to other therapeutic areas.
Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking.
MIAMI, FL / ACCESS Newswire / March 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA"), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, announced today that it has signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals, Inc. The transaction includes a
Under the terms of the LOI, MIRA will acquire SKNY through a stock exchange, whereby SKNY shareholders will receive shares of MIRA common stock at a valuation determined by an independent third-party firm. Additionally, SKNY will contribute
Targeting the Two Leading Causes of Preventable Death
According to a study published in The New England Journal of Medicine, smoking and obesity are the two leading causes of preventable death in the United States. According to the study, smoking is responsible for approximately
The acquisition of SKNY Pharmaceuticals strategically positions MIRA to enter two high-growth pharmaceutical markets with a differentiated, next-generation oral therapy that has the potential to improve patient outcomes.
Weight Loss: A
The global weight loss drug market is projected to surpass
SKNY-1, which is in preclinical development, is being investigated as a potential oral therapeutic option that may offer an innovative approach to metabolic regulation. The drug candidate is designed to interact with cannabinoid receptors CB1 and CB2 pathways that have been demonstrated for their role in appetite, metabolism, and energy balance regulation. If successful, SKNY-1 could address the growing demand for safe and effective weight loss solutions in a market that continues to expand.
Smoking Cessation: A Nearly
Despite a declining smoking rate, approximately 46 million U.S. adults still use tobacco products, including cigarettes, e-cigarettes, cigars, and smokeless tobacco (Source: PMC). The U.S. smoking cessation market is projected to grow from
Current FDA-approved smoking cessation treatments have low efficacy and significant side effects, leading to high discontinuation rates. SKNY-1 is being developed as a potential oral therapy that may work by modulating cannabinoid pathways involved in nicotine dependence. If successful, it could provide an alternative to existing treatments by addressing key challenges in smoking cessation.
CEO Perspective: Strengthening Mira's Market Position and Financial Standing
"Acquiring SKNY Pharmaceuticals marks a transformative step for MIRA," said Erez Aminov, Chairman and CEO of MIRA. "Obesity and smoking remain two of the most pressing public health challenges, yet current treatments have significant limitations. By integrating SKNY-1 into our pipeline, we are expanding into areas of high unmet medical need while strategically positioning MIRA for long-term growth and value creation."
Scientific Perspective: Reviewing the Data and Moving Forward
"After reviewing the preclinical data on SKNY-1, I am excited about the drug's pharmacological profile and its potential to become a game-changer in addressing two of the most urgent public health concerns-obesity and smoking," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "With extensive experience in cannabinoid-based drug development and metabolic research, I see significant promise in SKNY-1's approach to modulating key pathways involved in body weight, metabolic regulation and nicotine dependence."
Next Steps & Closing Conditions
MIRA Pharmaceuticals and SKNY Pharmaceuticals will conduct due diligence during a 90-day period, with both parties working toward executing a definitive agreement. The transaction is subject to regulatory approvals, board approvals, and final due diligence review. Upon closing, SKNY-1 will be fully integrated into MIRA's development pipeline, with plans to accelerate its path toward further preclinical evaluation.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the acquisition transaction and claims regarding SKNY-1. Any forward-looking statements in this press release are based on Mira's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
info@mirapharma.com
(786) 432-9792
SOURCE: MIRA Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the value of the capital infusion MIRA (NASDAQ:MIRA) will receive from the SKNY acquisition?
How will MIRA's acquisition of SKNY Pharmaceuticals be structured?
What are the target markets for SKNY-1, MIRA's newly acquired drug candidate?
How does SKNY-1 differ from current weight loss treatments like Wegovy and Ozempic?
What is the current development stage of SKNY-1 and when will the acquisition close?
